OTLK — OUTLOOK THERAPEUTICS INC

OUTLOOK THERAPEUTICS INC (OTLK) is a biotechnology company listed on NASDAQ. It is led by Lawrence A. Kenyon CPA, based in 111 S. Wood Avenue, Iselin, NJ, United States, 08830, with about 23 employees. Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.

Net income was -$47.8M. OTLK currently screens at market cap $68.6M and trailing P/E 0.4.

Use this OTLK page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the OTLK quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the OTLK SEC filings page. Lician reads the product cache first so this HTML stays unique to OUTLOOK THERAPEUTICS INC even when a live quote feed is slow.